Cholestatic Liver Diseases: Therapeutic Options and Perspectives: In Honour of Hans Popper's 100th BirthdayU. Leuschner, U. Broomé, A. Stiehl Springer Science & Business Media, 30 jun 2004 - 396 páginas During the last decade, knowledge about cholestatic liver disease and concomitant diseases, such as ulcerative colitis, cholangio- and hepatocellular carcinoma, pancreas and colon cancer, has increased considerably. Studies on ursodeoxycholic acid treatment alone or in combination with immunosuppressive compounds and their positive effects on biliary liver disease as well as on so-called overlap syndromes or intestinal tumors are published in increasing numbers, and stimulate discussion on whether or not ursodeoxycholic acid is able to improve the general condition and/or life expectancy of patients. On the other hand, genetics, aetiological and pathogenetic aspects are still difficult to comprehend, but are the absolute prerequisite for the development of better treatment options. This book is the proceedings of Falk Symposium No. 136 (Part I of the XII Falk Liver Week, held in Freiburg, Germany, on October 15-16, 2003), and contains stimulating, exciting and controversial papers on clinical and also basic research at the highest scientific level. |
Índice
Epidemiology of primary biliary cirrhosis | 3 |
Genetic components of primary biliary cirrhosis | 13 |
Infectious aetiology of primary biliary cirrhosis | 27 |
Gender and primary biliary cirrhosis is microchimerism an aetiological factor? | 37 |
HISTOLOGY AND IMMUNOLOGY OF PRIMARY BILIARY CIRRHOSIS AND AUTOIMMUNE CHOLESTATIC DISEASE | 45 |
Histology of autoimmune cholestatic liver diseases | 47 |
Mechanisms of biliary epithelial cell apoptosis in primary biliary cirrhosis | 56 |
Role of autoantibodies and autoantigens in primary biliary cirrhosis | 69 |
Incidence and prevalence of primary sclerosing cholangitis around the world | 218 |
Small duct primary sclerosing cholangitis a separate disease? | 225 |
Prognosis of untreated primary sclerosing cholangitis | 231 |
PRIMARY SCLEROSING CHOLANGITIS AN AUTOIMMUNE DISEASE? | 241 |
Is primary sclerosing cholangitis an autoimmune disease? | 243 |
Autoimmune markers and their role in the pathogenesis of primary sclerosing cholangitis | 247 |
The HLA system and other genetic markers in primary sclerosing cholangitis | 257 |
Viruses protozoans bacteria and drugs as aetiological factors in primary sclerosing cholangitis | 273 |
CLINICS OF PRIMARY BILIARY CIRRHOSIS | 77 |
Clinical aspects and prognosis of primary biliary cirrhosis | 79 |
Pathogenesis of pruritus and fatigue in cholestatic liver disease | 94 |
Is osteoporosis a specific complication of primary biliary cirrhosis? | 110 |
Diseases associated with primary biliary cirrhosis | 117 |
OVERLAP SYNDROMES | 123 |
Overlap syndromes outlier syndromes and changing diagnoses | 125 |
The autoimmune hepatitishepatitis C overlap syndrome does it exist? | 132 |
Histopathology of overlap syndromes in the liver | 147 |
TREATMENT OF PRIMARY BILIARY CIRRHOSIS | 159 |
Mechanisms of action of ursodeoxycholic acid in cholestasis | 161 |
Primary biliary cirrhosis longterm therapy with ursodeoxycholic acid | 171 |
Combination therapy of primary biliary cirrhosis and overlap syndromes | 179 |
Management of pruritus fatigue and bone disease in patients with primary biliary cirrhosis | 188 |
Liver transplantation rejection and disease recurrence | 197 |
DIAGNOSIS EPIDEMIOLOGY AND PROGNOSIS OF PRIMARY SCLEROSING CHOLANGITIS | 201 |
Primary sclerosing cholangitis diagnosis and differential diagnosis | 203 |
PRIMARY SCLEROSING CHOLANGITIS AND ASSOCIATED DISEASES | 281 |
Primary sclerosing cholangitis and inflammatory bowel disease when and how do they relate to each other? | 283 |
Extrahepatic and extraintestinal manifestations of primary sclerosing cholangitis | 289 |
Primary sclerosing cholangitis in paediatrics what is different? | 293 |
TREATMENT OPTIONS IN PRIMARY SCLEROSING CHOLANGITIS | 299 |
Ursodeoxycholic acid highdose monotherapy or combination therapy? | 301 |
Endoscopic treatment of dominant stenoses in patients with primary sclerosing cholangitis | 309 |
How should and how does antifibrotic therapy act in biliary fibrosis? | 314 |
Ursodeoxycholic acid to prevent colon cancer in primary sclerosing cholangitis | 323 |
MALIGNANCIES IN PRIMARY SCLEROSING CHOLANGITIS | 333 |
Hepatocellular carcinoma cholangiocarcinoma colon and pancreatic carcinoma in patients with primary sclerosing cholangitis epidemiology and risk ... | 335 |
Tumour markers and genetic markers in the diagnosis of bile duct carcinoma | 345 |
Histology and brush cytology for diagnosis of bile duct carcinoma in primary sclerosing cholangitis | 354 |
Primary sclerosing cholangitis indications for and recurrence after transplantation | 364 |
| 379 | |
Otras ediciones - Ver todo
Cholestatic Liver Diseases: Therapeutic Options and Perspectives: In honour ... U. Leuschner,U. Broomé,A. Stiehl No hay ninguna vista previa disponible - 2004 |
Términos y frases comunes
activation alleles antibodies antigens antimitochondrial apoptosis associated asymptomatic autoantibodies autoimmune diseases autoimmune hepatitis autoimmune liver disease bile acids bile duct bilirubin Boberg carcinoma cholangiocarcinoma cholangiocytes cholangiography cholestasis cholestatic cholestatic liver disease chronic hepatitis Clin clinical colon cancer colorectal cytokines Czaja diagnosis duct PSC dysplasia effect of UDCA endoscopic extrahepatic Falk Symposium fatigue fibrosis follow-up frequency Gastroenterology genes genetic haplotypes hepatobiliary hepatocytes Hepatology histological immune increased inflammation inflammatory bowel disease intrahepatic ISBN lesions Lindor KD liver biopsy liver transplantation lymphocytes malignancy markers Mayo molecules necrosis osteoporosis overlap syndrome pathogenesis patients with primary patients with PSC polymorphisms portal tracts Poupon prevalence primary biliary cirrhosis primary sclerosing cholangitis prognostic protein pruritus PSC patients receptor recurrence reported risk factors score serum small duct specific stage survival therapy tissue treatment tumour UDCA ulcerative colitis ursodeoxycholic acid viral Wiesner RH